Literature DB >> 31599856

The Role of Surgery in High-risk Neuroblastoma.

Anne L Ryan1,2, Adesola Akinkuotu3, Agostino Pierro3, Daniel A Morgenstern1, Meredith S Irwin1.   

Abstract

Although intensive multimodal treatment has improved outcomes for patients with high-risk neuroblastoma, the specific role of primary tumor resection remains controversial. Many studies have been designed to determine whether the extent of surgical resection impacts survival; however, these reports have demonstrated conflicting results. There is also ongoing debate regarding the timing of primary tumor resection, with subtle differences in the approach between the large pediatric oncology cooperative consortia. Most of the published literature to date has been approached from a surgical viewpoint. Although most evidence supports surgery as part of the local control approach for high-risk neuroblastoma, recommendations for timing and extent of surgical resection are not consistent. This review summarizes our current understanding from the perspectives of both the pediatric oncologist and pediatric surgeons and discusses how the objectives of neuroblastoma primary surgical resection are different from that of other malignancies. Furthermore, this commentary will address how retrospective surgical outcome data may be interpreted in the setting of modern era high-risk neuroblastoma treatment.

Entities:  

Mesh:

Year:  2020        PMID: 31599856     DOI: 10.1097/MPH.0000000000001607

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients.

Authors:  Erin K Barr; Kathryn Laurie; Kristen Wroblewski; Mark A Applebaum; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2020-07-25       Impact factor: 3.167

2.  Changes in image-defined risk factors with neoadjuvant chemotherapy in pediatric abdominal neuroblastoma.

Authors:  Haoru Wang; Xin Chen; Jin Zhu; Ke Zhang; Jiandong Lu; Li Zhang; Hao Ding; Ling He
Journal:  Abdom Radiol (NY)       Date:  2022-07-05

3.  Upregulation of CD3ζ and L-selectin in antigen-specific cytotoxic T lymphocytes by eliminating myeloid-derived suppressor cells with doxorubicin to improve killing efficacy of neuroblastoma cells in vitro.

Authors:  Weili Xu; Suolin Li; Meng Li; Hui Zhou; Xiaofeng Yang
Journal:  J Clin Lab Anal       Date:  2021-12-03       Impact factor: 2.352

4.  Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis.

Authors:  Jillian C Jacobson; Jingbo Qiao; Rachael A Clark; Dai H Chung
Journal:  Discov Oncol       Date:  2022-10-13

Review 5.  Molecular targeting therapies for neuroblastoma: Progress and challenges.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2020-11-06       Impact factor: 12.944

Review 6.  Surgical Approaches to Neuroblastoma: Review of the Operative Techniques.

Authors:  Federica Fati; Rebecca Pulvirenti; Irene Paraboschi; Giuseppe Martucciello
Journal:  Children (Basel)       Date:  2021-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.